The following is an excerpt from an update from Genentech. Read the update in its entirety here.
Genentech has provided a statement surrounding an August 27, 2020 US Federal Circuit Court of Appeals ruling which  reverses a previous ruling by the US District Court.
In December 2018, the US District Court issued a patent interpretation judgment that Hemlibra did not infringe upon a Baxalta patent. The US Federal Circuit of Appeals decision last week reverses that judgment and returns the case back to the US District Court.
Read the update in its entirety here.
HFA will NOT engage in the dialogue around patent ownership and will not be ‘choosing a side’ relative to this suit.  HFA will remain focused on patient access to care and if and when we feel that is being jeopardized, we will take any and all action necessary to ensure patient access to their prescribed therapies is not interrupted or denied. We are hopeful that both sides will conduct themselves in a way that will not jeopardize the health of the patients in the bleeding disorders community.
Please note that  HFA does not recommend, endorse or make any representation about the efficacy, appropriateness or suitability of any specific products, treatments, or opinions. Please consult your physician before use of any treatments.
